Arrowhead Pharmaceuticals (ARWR) Reports Q4 Loss of $1.34

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q4 EPS of ($1.34), versus ($1.60) reported last year. Revenue for the quarter came in at $158.33 thousand versus the consensus estimate of $382 thousand.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals (ARWR) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• S&P 500 may pull back before midterms, but Citi says buy the dip
• UBS Upgrades Apollo Tyres (APTY:IN) to Buy